organ transplantation, neuroscience, etc.
Novartis India Limited has announced a board meeting to consider and approve the financial results for the quarter and half-year. This is a crucial update for shareholders, as the meeting will determine and disclose the company's performance during this period. The company has also published newspaper advertisements to inform all...
Novartis India has announced that its Board has approved the appointment of M/s. D.C. Dave & Co., a firm of Practicing Cost Accountants, as the company's Cost Auditor. This appointment is for the financial year 2025-26, effective from April 1, 2025. This move is crucial for ensuring the company's cost...
Novartis India's share transfer agent confirmed the accurate processing of all dematerialized shares for the quarter ending June 30. This ensures that shares converted from physical to electronic format were correctly registered and listed on stock exchanges. Physical certificates received were properly cancelled, and company records were updated with the...
Novartis India Limited has announced a board meeting to discuss the financial results for the quarter and half-year. The company has also scheduled its 77th Annual General Meeting to be held via video conferencing. The Annual Report for FY 2024-25 is available online, and shareholders who have not registered their...
Novartis India has announced a board meeting on July 31, 2025, to consider the financial results for the quarter and half-year. The company has completed dispatching the Notice of its 77th Annual General Meeting (AGM) along with the Annual Report for FY 2024-25 to shareholders through electronic mode. The AGM...
